PDF(982 KB)
Effects of Huaiqihuang granules on immune function in children with severe Mycoplasma pneumoniae pneumonia
LIU Jin, YAN Hong, CHEN Xiao-Geng, MU Ya-Ping
Chinese Journal of Contemporary Pediatrics ›› 2017, Vol. 19 ›› Issue (7) : 759-762.
PDF(982 KB)
PDF(982 KB)
Effects of Huaiqihuang granules on immune function in children with severe Mycoplasma pneumoniae pneumonia
Objective To observe the effects of Huaiqihuang granules on the immune function in children with severe Mycoplasma pneumoniae pneumonia. Methods Pediatric inpatients with severe Mycoplasma pneumoniae pneumonia were randomly divided into Huaiqihuang granule treatment group (n=51) and conventional treatment group (n=47). The Huaiqihuang granule treatment group was orally administered Huaiqihuang granules in addition to the conventional treatment, while the conventional treatment group received conventional treatment only. Levels of serum IgA, IgG, and IgM, percentages of CD4+ and CD8+ T lymphocyte subsets, and CD4+/CD8+ ratio were examined in the two groups. The incidence rate of respiratory tract re-infection within three months following treatment was compared between the two groups. Results The levels of serum IgA, IgG, and IgM, the percentage of CD4+ T lymphocytes, and the CD4+/CD8+ ratio were significantly higher in the Huaiqihuang granule treatment group than in the conventional treatment group three months after treatment (P < 0.05). In contrast, the percentage of CD8+ T lymphocytes was signifcantly lower in the Huaiqihuang granule treatment group than in the conventional treatment group (P < 0.05). In addition, the incidence rate of respiratory tract re-infection within three months following treatment was signifcantly lower in the Huaiqihuang granule treatment group than in the conventional treatment group (P < 0.05). Conclusions Huaiqihuang granules can regulate immune functions and reduce the incidence of short-term respiratory tract re-infection in children with severe Mycoplasma pneumoniae pneumonia.
Huaiqihuang granule / Mycoplasma pneumoniae pneumonia / Immune / Child
[1] Meyer Sauteur PM, Unger WW, Nadal D, et al. Infection with and carriage of Mycoplasma pneumoniae in children[J]. Front Microbiol, 2016, 7:329.
[2] Medjo B, Atanaskovic-Markovic M, Radic S, et al. Mycoplasma pneumoniae as a causative agent of community-acquired pneumonia in children:clinical features and laboratory diagnosis[J]. Ital J Pediatr, 2014, 40:104.
[3] 侯安存, 卢炎, 沙莉, 等. 支原体肺炎患儿辅助性T淋巴细胞亚群TH1、TH2细胞状况[J]. 中华儿科杂志, 2003, 41(9):652-656.
[4] 张书琳, 崔岚巍. 槐耳及其复方制剂槐杞黄颗粒的研究进展[J]. 医学综述, 2015, 21(1):114-116.
[5] 中华医学会儿科学分会呼吸学组,《中华实用儿科临床杂志》 编辑委员会. 儿童肺炎支原体肺炎诊治专家共识(2015年版)[J]. 中华实用儿科临床杂志, 2015, 30(17):1304-1308.
[6] 中华医学会儿科学分会呼吸学组, 《中华儿科杂志》编辑委员会. 儿童社区获得性肺炎管理指南(2013修订)(上)[J]. 中华儿科杂志, 2013, 51(10):745-752.
[7] 中华医学会儿科学分会呼吸学组, 《中华儿科杂志》编辑委员会. 儿童社区获得性肺炎管理指南(2013修订)(下)[J]. 中华儿科杂志, 2013, 51(11):856-862.
[8] Yamazaki T, Kenri T. Epidemiology of Mycoplasma pneumoniae infections in Japan and therapeutic strategies for macrolideresistant M. pneumonia[J]. Front Microbiol, 2016, 7:693.
[9] Diaz MH, Benitezk AJ, Winchell JM. Investigations of Mycoplasma pneumoniae infections in the United States:trends in molecular typing and macrolide resistance from 2006 to 2013[J]. J Clin Microbiol, 2015, 53(1):124-130.
[10] Zhou Z, Li X, Chen X, et al. Macrolide-resistant Mycoplasma pneumoniae in adults in Zhejiang, China[J]. Antimicrob Agents Chemother, 2015, 59(2):1048-1051.
[11] 叶婷婷, 王黎萍, 田少江, 等. 槐杞黄颗粒对慢性肾衰竭患者细胞免疫功能的影响[J]. 中国中西医结合肾病杂志, 2014, 14(3):254-255.
[12] 卜红南. 黄精多糖的提取及其免疫活性研究[J]. 实用医药杂志, 2017, 34(1):48-56.
[13] 赵恰莎. 槐杞黄颗粒对反复呼吸道感染患儿免疫功能影响的研究[J]. 新中医, 2015, 47(4):203-204.
[14] 钱一超. 支原体肺炎儿童的免疫功能变化分析[J]. 中国妇幼保健, 2016, 31(7):1432-1434.
[15] Zhang Y, Zhou Y, Li S, et al. The clinical characteristics and predictors of refractory mycoplasma pneumoniae pneumonia in children[J]. PLoS One, 2016, 11(5):e0156465.
